CTI Pharma

Years in the unmaking, CTI’s Pixuvri fails a pivotal PhIII combo study for lymphoma — can it remain on the market?
Endpoints
Mon, 07/9/18 - 12:00 pm
CTI Pharma
Pixuvri
B-cell non-Hodgkin lymphoma
clinical trials